- Home
- INVA vs OLMA Comparison
INVA vs OLMA Comparison
Compare INVA & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVA | OLMA |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INVA | OLMA |
|---|---|---|
| Price | $22.42 | $13.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $32.80 | ★ $44.89 |
| AVG Volume (30 Days) | 584.5K | ★ 877.5K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 816.67 | 15.00 |
| EPS | ★ 2.22 | N/A |
| Revenue | ★ $217,217,000.00 | N/A |
| Revenue This Year | $8.95 | N/A |
| Revenue Next Year | $12.65 | N/A |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | ★ 62.63 | N/A |
| 52 Week Low | $16.52 | $3.89 |
| 52 Week High | $25.15 | $36.26 |
Technical Indicators
Market Signals| Indicator | INVA | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 40.07 |
| Support Level | $21.91 | $13.54 |
| Resistance Level | $22.76 | $17.23 |
| Average True Range (ATR) | 0.74 | 0.88 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 38.66 | 32.61 |
Price Performance
Historical ComparisonAbout INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.